Legal/Regulatory

Five things for pharma marketers to know: Wednesday, July 26, 2017

Five things for pharma marketers to know: Wednesday, July 26, 2017

By

Jury says AbbVie fraudulently misrepresented risks of AndroGel; Celgene settles False Claims Act lawsuit; Amgen reports more Repatha prescribers

Five things for pharma marketers to know: Wednesday, July 12, 2017

Five things for pharma marketers to know: Wednesday, July 12, 2017

By

Former sales reps for Insys plead guilty to kickback allegations; digital health funding on the rise; PhRMA launches campaign about drug costs

The FDA attempts to understand how disclosures affect drug ads

The FDA attempts to understand how disclosures affect drug ads

By

The FDA recently proposed studies designed to determine how disclosures in drug ads affect how viewers frame information.

Astellas reprimanded by U.K. drug regulator

Astellas reprimanded by U.K. drug regulator

By

The drugmaker has been handed a "public reprimand" by the U.K.'s Prescription Medicines Code of Practice Authority after the creative director of an unnamed agency used the company's patient support materials on its website.

What marketers need to know about tax reform, off-label promotion, pricing

What marketers need to know about tax reform, off-label promotion, pricing

By

The ad-tax deduction is likely once again on the table.

Amgen, Sandoz argue biosimilar patent case to the Supreme Court

Amgen, Sandoz argue biosimilar patent case to the Supreme Court

By

Sandoz counsel argued that Amgen's position "wrongly delays the marketing of every biosimilar."

PhRMA debuts new ads in Go Boldly campaign

PhRMA debuts new ads in Go Boldly campaign

By

PhRMA worked with WPP Health & Wellness and Young & Rubicam on creative for the ads.

Five things for pharma marketers to know: Friday, April 14, 2017

Five things for pharma marketers to know: Friday, April 14, 2017

By

Lawmaker wants better enforcement of TV ads placed by lawyers; more toddlers are taking antipsychotics; Neurocrine puts off price disclosure of new drug

Senate committee launches investigation into opioid marketing

Senate committee launches investigation into opioid marketing

By

The committee is seeking information about the companies' sales and marketing strategies.

Veeva and QuintilesIMS tussle over customer reference data

Veeva and QuintilesIMS tussle over customer reference data

By

Veeva is countersuing QuintilesIMS in the wake of allegations that Veeva mishandled its proprietary data.

Industry groups petition the FDA over off-label rule

Industry groups petition the FDA over off-label rule

By

PhRMA, BIO, and the Medical Information Working Group filed a citizen petition over a final rule they say raises risks for drugmakers.

FDA guidance seeks to clarify pharma comms with payers

FDA guidance seeks to clarify pharma comms with payers

By

But it may also increase the reporting burden for drugmakers.

In draft guidance, the FDA defines appropriate off-label comms as being 'consistent' with the label

In draft guidance, the FDA defines appropriate off-label comms as being 'consistent' with the label

By

The regulator is providing examples of appropriate off-label communications.

The FDA targeted DTC, video, unapproved drug promotion in 2016

The FDA targeted DTC, video, unapproved drug promotion in 2016

By

The agency issued 11 enforcement letters last year.

Five things for pharma marketers to know: Friday, January 6, 2017

Five things for pharma marketers to know: Friday, January 6, 2017

By

Judge halts Praluent sales; clinical-trial data for Diclegis in question; cancer drugs to make up larger portion of total drug spending

The FDA to study whether people can recognize misleading drug ads

The FDA to study whether people can recognize misleading drug ads

The agency has faced questions about how it regulates off-label communications.

Five things for pharma marketers to know: Wednesday, December 28, 2016

Five things for pharma marketers to know: Wednesday, December 28, 2016

By

Sanofi sues Novo over Tresiba marketing; the FDA issues two more untitled letters; U.S. health spending rose substantially from 1996 to 2013

Five things for pharma marketers to know: Thursday, December 22, 2016

Five things for pharma marketers to know: Thursday, December 22, 2016

By

Senate report said certain drugmakers act like hedge funds; ViiV to develop HIV prevention drug; lawmakers to replace ACA with "universal access"

Five things for pharma marketers to know: Friday, December 16, 2016

Five things for pharma marketers to know: Friday, December 16, 2016

By

Allergan to settle allegations relating to speakers bureaus; Mylan launches generic version of the EpiPen; 20 states sue six drugmakers accused of price-fixing

The FDA issues untitled letters to Sanofi and Celgene over distracting ads

The FDA issues untitled letters to Sanofi and Celgene over distracting ads

By

Regulators said the ads distract viewers from superimposed safety information.

The FDA extends deadline for off-label input

The FDA extends deadline for off-label input

By

The previous deadline was January 9.

Five things for pharma marketers to know: Thursday, December 8, 2016

Five things for pharma marketers to know: Thursday, December 8, 2016

By

A California lawmaker reintroduces drug-pricing bill; France, Poland, Spain, and Sweden lobby to host EMA; drug stocks fall after Trump's comments

Senate passes Cures Act, which opens door to use of real-world evidence

Senate passes Cures Act, which opens door to use of real-world evidence

By

The bill now heads to President Obama's desk. He is expected to sign the sweeping piece of legislation.

House passes 21st Century Cures Act that would allow some off-label sharing

House passes 21st Century Cures Act that would allow some off-label sharing

By

The bill includes two provisions that would address drugmakers' calls for clarity on sharing off-label information with payers and regulators.

Five things for pharma marketers to know: Tuesday, November 15, 2016

Five things for pharma marketers to know: Tuesday, November 15, 2016

By

The CMS spent more on Harvoni than any other drug; Novartis considers selling Alcon; the EMA recommends approval of Lantus biosimilar

Five things for pharma marketers to know: Friday, November 11, 2016

Five things for pharma marketers to know: Friday, November 11, 2016

By

Trump says he will reform the FDA; pharmaceutical M&A expected to pick up; superbug causing infections in cystic-fibrosis patients

5 questions raised at the FDA's off-label hearing

5 questions raised at the FDA's off-label hearing

By

The FDA asked questions about the risks and benefits of allowing off-label communications.

Five things for pharma marketers to know: Tuesday, November 8, 2016

Five things for pharma marketers to know: Tuesday, November 8, 2016

By

FDA solicits public comment to study online character space limit; Biogen's Spinraza shows positive results in SMA study; Valeant cuts earnings forecast

Will drugmakers get what they're looking for at this week's FDA off-label hearing?

Will drugmakers get what they're looking for at this week's FDA off-label hearing?

By

Spurred by recent lawsuits, the FDA is scheduled to hold a two-day hearing this week on whether to allow drugmakers more latitude in promoting therapies off-label.

Off-label promotion: By the numbers

Off-label promotion: By the numbers

By

Here are 5 statistics about off-label promotion ahead of the FDA's public hearing this week.